eLife (Mar 2022)

The out-of-field dose in radiation therapy induces delayed tumorigenesis by senescence evasion

  • Erwan Goy,
  • Maxime Tomezak,
  • Caterina Facchin,
  • Nathalie Martin,
  • Emmanuel Bouchaert,
  • Jerome Benoit,
  • Clementine de Schutter,
  • Joe Nassour,
  • Laure Saas,
  • Claire Drullion,
  • Priscille M Brodin,
  • Alexandre Vandeputte,
  • Olivier Molendi-Coste,
  • Laurent Pineau,
  • Gautier Goormachtigh,
  • Olivier Pluquet,
  • Albin Pourtier,
  • Fabrizio Cleri,
  • Eric Lartigau,
  • Nicolas Penel,
  • Corinne Abbadie

DOI
https://doi.org/10.7554/eLife.67190
Journal volume & issue
Vol. 11

Abstract

Read online

A rare but severe complication of curative-intent radiation therapy is the induction of second primary cancers. These cancers preferentially develop not inside the planning target volume (PTV) but around, over several centimeters, after a latency period of 1–40 years. We show here that normal human or mouse dermal fibroblasts submitted to the out-of-field dose scattering at the margin of a PTV receiving a mimicked patient’s treatment do not die but enter in a long-lived senescent state resulting from the accumulation of unrepaired DNA single-strand breaks, in the almost absence of double-strand breaks. Importantly, a few of these senescent cells systematically and spontaneously escape from the cell cycle arrest after a while to generate daughter cells harboring mutations and invasive capacities. These findings highlight single-strand break-induced senescence as the mechanism of second primary cancer initiation, with clinically relevant spatiotemporal specificities. Senescence being pharmacologically targetable, they open the avenue for second primary cancer prevention.

Keywords